Curative effects of phosphodiesterase 4 inhibitors cilomilast, roflumilast, and rolipram in dermatitis mouse model.
Harada
Daisuke
D
Ikeda
Yoshimi
Y
Nosaka
Yukino
Y
Kobayashi
Katsuya
K
Manabe
Haruhiko
H
D000631:Aminopyridines / Q000627:therapeutic use; D000818:Animals; D001549:Benzamides / Q000627:therapeutic use; D002264:Carboxylic Acids / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids; D003521:Cyclopropanes / Q000627:therapeutic use; D003872:Dermatitis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D003877:Dermatitis, Contact / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D004195:Disease Models, Animal; D047209:Eosinophil Peroxidase / Q000378:metabolism; D015847:Interleukin-4 / Q000378:metabolism; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009570:Nitriles / Q000627:therapeutic use; D009195:Peroxidase / Q000378:metabolism; D058988:Phosphodiesterase 4 Inhibitors; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010853:Picryl Chloride / Q000633:toxicity; D020889:Rolipram / Q000627:therapeutic use
D000631:Aminopyridines; D001549:Benzamides; D002264:Carboxylic Acids; D003509:Cyclohexanecarboxylic Acids; D003521:Cyclopropanes; D009570:Nitriles; D058988:Phosphodiesterase 4 Inhibitors; D010726:Phosphodiesterase Inhibitors; C424423:Roflumilast; D015847:Interleukin-4; C433247:Cilomilast; D047209:Eosinophil Peroxidase; D009195:Peroxidase; D020889:Rolipram; D010853:Picryl Chloride